Evaluation of Blood Volume Analysis- Guided Management of Decompensated Heart Failure

NACompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Acute Decompensated Heart Failure
Interventions
DIAGNOSTIC_TEST

BVA-100

The BVA-100 is a medical device that calculates human blood volume using the method of tracer dilution. The device utilizes a tracer of human serum albumin tagged with iodine-131 to measure injected intravascularly and a series of timed blood draws. The amount of tracer in each blood draw is used to calculate the unknown blood volume. Data inputs come from the measured characteristics of subject blood samples (hematocrit and tracer concentration) and tracer calibration standards. The package also calculates the subject expected (or ideal) blood volume from physical parameters. Hyper- or hypovolemia, associated red blood cell volumes, and tracer transudation rate are reported, with statistics showing the quality of the results.

Trial Locations (1)

02130

VA Boston Healthcare System, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

VA Boston Healthcare System

FED

collaborator

Minneapolis Veterans Affairs Medical Center

FED

lead

Daxor Corporation

INDUSTRY

NCT04855097 - Evaluation of Blood Volume Analysis- Guided Management of Decompensated Heart Failure | Biotech Hunter | Biotech Hunter